Gregory McMahon, DO
Urology · Wynnewood, PANPI 1295116218
Payments from drug & device makers
Across 369 payments — averaging $214.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$48K
- Janssen Scientific Affairs, LLC$9K
- Bayer$5K
- Ferring Pharmaceuticals Inc.$5K
- Astellas Pharma US Inc$3K
- Telix Pharmaceuticals$2K
- plus $7K from 37 others
What the payments were for
- Consulting fees$43,24055%
- Speaking & faculty fees$20,82826%
- Travel & lodging$4,1025%
- Food & beverage$10,92914%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 142 | $47,740 |
| Janssen Scientific Affairs, LLC | 11 | $9,471 |
| Bayer | 40 | $5,004 |
| Ferring Pharmaceuticals Inc. | 9 | $4,768 |
| Astellas Pharma US Inc | 20 | $2,980 |
| Telix Pharmaceuticals | 11 | $1,999 |
| AstraZeneca | 9 | $1,561 |
| Janssen Global Services, LLC | 2 | $1,267 |
| Boston Scientific | 8 | $719 |
| Dendreon Pharmaceuticals LLC | 12 | $563 |
| Teleflex LLC | 5 | $382 |
| Immunitybio, Inc. | 9 | $378 |
| Tolmar, Inc. | 10 | $266 |
| Angiodynamics, Inc. | 2 | $242 |
| Novartis | 9 | $237 |
| Pfizer | 11 | $196 |
| Axonics, Inc. | 6 | $166 |
| Merck | 5 | $159 |
| AbbVie | 6 | $134 |
| Sumitomo Pharma America, Inc. | 6 | $118 |
| Coloplast | 1 | $98 |
| Verity Pharmaceuticals Inc. | 4 | $83 |
| Myriad Genetic Laboratories, Inc. | 5 | $80 |
| Bioprotect Medical, Inc. | 4 | $75 |
| Urogen Pharma, Inc. | 3 | $73 |
| Dentsply IH AB | 1 | $47 |
| Calyxo, Inc. | 2 | $45 |
| Civco Medical Instruments | 1 | $38 |
| Medtronic | 1 | $31 |
| Progenics Pharmaceuticals, Inc. | 1 | $30 |
| Profound Medical Corp. | 1 | $28 |
| Millicent US Inc | 1 | $23 |
| Accord Healthcare, Inc. | 1 | $23 |
| Olympus America Inc. | 1 | $22 |
| Mimedx Group, Inc. | 1 | $21 |
| Vertex | 1 | $20 |
| Sandoz | 1 | $19 |
| Tempus AI, Inc | 1 | $18 |
| 180 Medical, Inc. | 1 | $18 |
| Avation Medical, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Endo USA, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBREVANT$23,874
- CARVYKTI$23,874
- Erleada$6,740
- ADSTILADRIN$4,666
- Nubeqa$4,309
- Xofigo$3,243
- XTANDI$2,484
- IMFINZI$1,395
- SpaceOAR System$450
- PROVENGE$276
- ANKTIVA$256
- UroLift System$250
- Nanoknife$221
- GENERAL ERECTILE DYSFUNCTION$148
- AKEEGA$126
- UroLift$104
How this compares
$79,202 in reported general payments places this provider in the 90th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 155 | $2,161,771 |
| XtandiEnzalutamide | 80 | $1,008,923 |
| OrgovyxRelugolix | 276 | $776,378 |
| NubeqaDarolutamide | 31 | $399,040 |
| Abiraterone Acetate | 94 | $182,722 |
| MyrbetriqMirabegron | 33 | $27,742 |
| Tamsulosin Hcl | 653 | $11,833 |
| GemtesaVibegron | 14 | $6,586 |
| Finasteride | 176 | $3,238 |
| Tadalafil | 11 | $1,797 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,654 |
| Oxybutynin Chloride ErOxybutynin Chloride | 63 | $1,604 |
| Silodosin | 15 | $1,322 |
| Doxazosin Mesylate | 51 | $1,299 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 73 | $401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $47,740 | $2,161,771155 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $2,980 | $1,036,665113 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $118 | $782,964290 claims |
| BayerNubeqa | $5,004 | $399,04031 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $9,471 | $182,72294 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 596 urology providers in Pennsylvania.
Other urology in Wynnewood
- Laurence BelkoffBala Cynwyd$18.7M
- Paul SieberLancaster$12.6M
- Costas LallasPhiladelphia$3.6M
- John AndersonBethlehem$2.1M
- Jodi MaranchiePittsburgh$1.2M
- Kenneth LessansLancaster$943K
- Stanley MalkowiczPhiladelphia$882K
- Demetrius BagleyPhiladelphia$739K
- Gregory TasianPhiladelphia$645K
- Eugene PietzakPhiladelphia$544K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.